Alnylam Pharmaceuticals Inc
ALNY307.990USD
+3.320+1.09%
Cierre 06/13, 16:00（ET）Cotizaciones retrasadas 15 min
40.13BCap. mercado
PérdidaP/E TTM
Más Datos de Alnylam Pharmaceuticals Inc Compañía
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Información de la empresa
Símbolo de cotizaciónALNY
Nombre de la empresaAlnylam Pharmaceuticals Inc
Fecha de salida a bolsaMay 28, 2004
Fundada en2003
Director ejecutivoDr. Yvonne L. Greenstreet, M.D.
Número de empleados2230
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 28
Dirección675 W Kendall St
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02142-1168
Teléfono16175518200
Sitio Webhttps://www.alnylam.com/
Símbolo de cotizaciónALNY
Fecha de salida a bolsaMay 28, 2004
Fundada en2003
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
49.35K
--
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
47.81K
+40.80%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
28.01K
+95.27%
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chief Compliance Officer, Director
Chief Compliance Officer, Director
20.80K
+3.87%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
+21.31%
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+569.85%
Ms. Carolyn R. Bertozzi, M.D.
Ms. Carolyn R. Bertozzi, M.D.
Independent Director
Independent Director
775.00
--
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
775.00
--
Mr. Peter N. Kellogg
Mr. Peter N. Kellogg
Independent Director
Independent Director
775.00
--
Ms. Colleen F. Reitan
Ms. Colleen F. Reitan
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
49.35K
--
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
47.81K
+40.80%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
28.01K
+95.27%
Mr. Michael W. (Mike) Bonney
Mr. Michael W. (Mike) Bonney
Chief Compliance Officer, Director
Chief Compliance Officer, Director
20.80K
+3.87%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
+21.31%
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+569.85%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de abr
Divisa: USDActualizado: dom., 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Por negocioUSD
Nombre
Ganancia
Proporción
AMVUTTRA
970.45M
43.16%
Regeneron Pharmaceuticals
302.80M
13.47%
GIVLAARI
255.87M
11.38%
ONPATTRO
252.86M
11.25%
OXLUMO
167.05M
7.43%
Other
299.22M
13.31%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
933.54M
41.52%
Europe
516.30M
22.96%
Net revenues from collaborations
510.22M
22.69%
Rest of World
196.39M
8.74%
Royalty revenue
91.79M
4.08%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
AMVUTTRA
970.45M
43.16%
Regeneron Pharmaceuticals
302.80M
13.47%
GIVLAARI
255.87M
11.38%
ONPATTRO
252.86M
11.25%
OXLUMO
167.05M
7.43%
Other
299.22M
13.31%
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Capital World Investors
12.85%
Fidelity Management & Research Company LLC
11.22%
The Vanguard Group, Inc.
9.97%
Capital Research Global Investors
5.49%
BlackRock Institutional Trust Company, N.A.
5.16%
Other
55.32%
Accionistas
Accionistas
Proporción
Capital World Investors
12.85%
Fidelity Management & Research Company LLC
11.22%
The Vanguard Group, Inc.
9.97%
Capital Research Global Investors
5.49%
BlackRock Institutional Trust Company, N.A.
5.16%
Other
55.32%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
57.08%
Investment Advisor/Hedge Fund
30.90%
Corporation
3.44%
Hedge Fund
3.14%
Sovereign Wealth Fund
2.00%
Research Firm
1.57%
Pension Fund
1.25%
Bank and Trust
1.12%
Individual Investor
0.39%
Participación institucional
Actualizado: dom., 19 de ene
Actualizado: dom., 19 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
1268
131.09M
100.54%
-4.40M
2024Q4
1263
130.73M
100.99%
-1.47M
2024Q3
1225
126.90M
98.51%
-1.26M
2024Q2
1183
123.30M
96.32%
+1.12M
2024Q1
1172
117.88M
93.23%
-5.46M
2023Q4
1169
120.70M
96.18%
-5.54M
2023Q3
1125
121.55M
96.89%
-6.15M
2023Q2
1119
122.11M
98.30%
-6.32M
2023Q1
1116
123.13M
99.37%
-5.56M
2022Q4
1103
122.98M
99.27%
-3.16M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Capital World Investors
16.60M
12.76%
+92.10K
+0.56%
Dec 31, 2024
Fidelity Management & Research Company LLC
12.94M
9.95%
-1.20M
-8.49%
Dec 31, 2024
The Vanguard Group, Inc.
13.06M
10.04%
+378.83K
+2.99%
Mar 31, 2025
Capital Research Global Investors
6.97M
5.36%
+1.72M
+32.89%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
6.75M
5.19%
+149.81K
+2.27%
Dec 31, 2024
Regeneron Pharmaceuticals Inc
4.44M
3.42%
+4.44M
--
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
4.38M
3.37%
+1.25M
+39.67%
Dec 31, 2024
Baillie Gifford & Co.
4.04M
3.11%
-846.74K
-17.33%
Dec 31, 2024
T. Rowe Price Associates, Inc.
3.23M
2.48%
-123.23K
-3.68%
Dec 31, 2024
State Street Global Advisors (US)
3.42M
2.63%
-45.44K
-1.31%
Dec 31, 2024
Ver más
ETFs relacionados
Actualizado: vie., 6 de jun
Actualizado: vie., 6 de jun
Nombre
Proporción
Tema Neuroscience and Mental Health ETF
5.15%
VanEck Biotech ETF
5.11%
Global X Genomics & Biotechnology ETF
4.67%
Invesco Nasdaq Biotechnology ETF
4.1%
First Trust NYSE Arca Biotechnology Index Fund
3.92%
ProShares Ultra Nasdaq Biotechnology
3.9%
iShares Biotechnology ETF
3.6%
American Century Focused Dynamic Growth ETF
3.44%
Franklin Genomic Advancements ETF
3.19%
SPDR S&P Biotech ETF
3.05%
Ver más
Tema Neuroscience and Mental Health ETF
Proporción5.15%
VanEck Biotech ETF
Proporción5.11%
Global X Genomics & Biotechnology ETF
Proporción4.67%
Invesco Nasdaq Biotechnology ETF
Proporción4.1%
First Trust NYSE Arca Biotechnology Index Fund
Proporción3.92%
ProShares Ultra Nasdaq Biotechnology
Proporción3.9%
iShares Biotechnology ETF
Proporción3.6%
American Century Focused Dynamic Growth ETF
Proporción3.44%
Franklin Genomic Advancements ETF
Proporción3.19%
SPDR S&P Biotech ETF
Proporción3.05%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
